To the best of our knowledge, this is the first study in patients with T2D and established CHF (almost all with NYHA class I to II and HFpEF) to assess whether the effects of a SGLT2 inhibitor on HF-related clinical parameters differ according to the baseline use of medications for T2D. Here, SLC5A2 is linked to type 2 diabetes mellitus.